Lead Product(s) : Imlunestrant,Abemaciclib,Trastuzumab
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lilly Announces Details of Presentations at 2022 San Antonio Breast Cancer Symposium
Details : Imlunestrant (LY3484356) is an investigational, oral selective estrogen receptor degrader (SERD) with pure antagonistic properties. The estrogen receptor (ER) is the key therapeutic target for patients with ER+/HER2- breast cancer.
Brand Name : LY3484356
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 21, 2022
Lead Product(s) : Imlunestrant,Abemaciclib,Trastuzumab
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?